Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 9/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618266 | 0.84 | L3MBTL3 (0.51) | MAPKAPK5TTKFLT3ACKR3IKBKB | |
| SCHEMBL5618766 | 0.80 | KDM4E (0.47) | MAPKAPK5TTKFLT3ADORA3ALDH1A1 | |
| SCHEMBL5618288 | 0.79 | MAPKAPK5 (0.55) | MAPKAPK5TTKFLT3ADORA3MAPT | |
| SCHEMBL5617937 | 0.75 | FLT3 (0.47) | MAPKAPK5TTKFLT3ADORA3 | |
| SCHEMBL5618395 | 0.75 | FLT3 (0.49) | MAPKAPK5TTKFLT3GAAADORA3 | |
| SCHEMBL14573309 | 0.71 | MAPKAPK5 (0.50) | MAPKAPK5TTKFLT3ADORA3 | |
| SCHEMBL14573306 | 0.68 | AKT3 (0.44) | MAPKAPK5TTKFLT3ACKR3IKBKB | |
| SCHEMBL5413984 | 0.67 | TTK (0.48) | TTKIKBKBALDH1A1 | |
| SCHEMBL5394371 | 0.67 | TTK (0.48) | TTKIKBKBALDH1A1 | |
| SCHEMBL5618824 | 0.67 | FLT3 (0.53) | MAPKAPK5TTKFLT3GAAIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | claimed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | MAPKAPK5 29/4885TTK 69/4885FLT3 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.